M
Michael Panzara
Researcher at Genzyme
Publications - 115
Citations - 12560
Michael Panzara is an academic researcher from Genzyme. The author has contributed to research in topics: Natalizumab & Multiple sclerosis. The author has an hindex of 30, co-authored 114 publications receiving 11553 citations. Previous affiliations of Michael Panzara include Stanford University & Harvard University.
Papers
More filters
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser,Emmanuelle Waubant,Douglas L. Arnold,Timothy Vollmer,Jack P. Antel,Robert J. Fox,Amit Bar-Or,Michael Panzara,Neena Sarkar,Sunil Agarwal,Annette Langer-Gould,Craig H. Smith +11 more
TL;DR: A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
Journal ArticleDOI
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Richard A. Rudick,WH Stuart,Peter A. Calabresi,Christian Confavreux,Steven L. Galetta,Ernst Wilhelm Radue,Fred D. Lublin,Bianca Weinstock-Guttman,Daniel Wynn,F Lynn,Michael Panzara,Alfred Sandrock +11 more
TL;DR: Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.
Journal ArticleDOI
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A. Cohen,Alasdair Coles,Douglas L. Arnold,Christian Confavreux,Edward Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Elizabeth Fisher,Vesna V. Brinar,Gavin Giovannoni,Miroslav Stojanovic,Bella Ertik,Stephen Lake,David Margolin,Michael Panzara,D Alastair S Compston +17 more
TL;DR: Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit interms of disability endpoints noted in previous trials was not observed here.
Journal ArticleDOI
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial
Alasdair Coles,Cary Twyman,Douglas L. Arnold,Jeffrey A. Cohen,Christian Confavreux,Edward Fox,Hans Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Rupert Sandbrink,Stephen Lake,David Margolin,Pedro Oyuela,Michael Panzara,D Alastair S Compston +18 more
TL;DR: This 2 year, rater-masked, randomised controlled phase 3 trial enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer and found alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability.